Assessment of Patients Affected by Rheumatoid Arthritis Eligible for Biotechnological Agents and Evaluation of Their Healthcare Resource Utilization and Related Costs. Reumatismo 2021, 73 (1), 5-14. https://doi.org/10.4081/reumatismo.2021.1329.